Neurogenic Inflammation: This is an inflammation rising from the release locally from afferent neurons of mediators of inflammatory such as substance P as well as calcitonin gene-lasted peptide or CGRP.
This is a process appearing to play a role that is important in the pathogenesis of frequent disease such as psoriasis, fibromyalgia, asthma, eczema, dystonia rosacea migraine and multiple sensitivity to chemicals.
In migraine, the stimulation of the trigeminal nerve triggers neurogenic inflammation via the release of neuropeptides such as substance P, vasoactive intestinal polypeptide, neurokinin A, nitric oxide 5-ht, and CGRP which leads to a “sterile neurogenic inflammation”.
The treatment for migraine with blockers of CGRP is showing promise. In trials, the 1st oral non-peptide CGRP antagonist, MK-0974 or Telcagepant was showing operational effectiveness in the management of migraine attacks but liver enzymes elevated in 2 subjects were found. Other links and other therapy in the neurogenic pathway for inflammation for disease interruption are under study including migraine therapies.
Botulinum toxin has been showing some effect on inhibiting “neurogenic inflammation” as well as indications that suggest the character of inflammation neurogenically in psoriasis pathogenesis. The University of Minnesota has started follow up trial to observe patients treated with botulinum toxin for dystonia has improvements that are dramatic in psoriasis.
Astelin or Azelastine is indicated for treatment symptomatically of rhinitis that is vasomotor including nasal congestion, rhinorrhea, as well as post nasal drip in children 12 years of age and older as well as adults.
Statins can be useful for treating these diseases that have predominant neurogenic inflammation.